Page 16 - Read Online

Fitzgerald et al. J Cancer Metastasis Treat 2021;7:54 https://dx.doi.org/10.20517/2394-4722.2021.97 Page 11 of 11

cisplatin and pemetrexed in chemonaive patients with malignant pleural mesothelioma. J Clin Oncol 2018;36:8514. DOI
10. Baas P, Scherpereel A, Nowak AK, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma
(CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet 2021;397:375-86. DOI PubMed
11. FDA Approves Drug Combination for Treating Mesothelioma. Available from: https://www.fda.gov/news-events/press-
announcements/fda-approves-drug-combination-treating-mesothelioma. [Last accessed on 4 Aug 2021].
12. Samstein RM, Lee CH, Shoushtari AN, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer
types. Nat Genet 2019;51:202-6. DOI PubMed PMC
13. Markowitz P, Patel M, Groisberg R, et al. Genomic characterization of malignant pleural mesothelioma and associated clinical
outcomes. Cancer Treat Res Commun 2020;25:100232. DOI PubMed
14. Alley EW, Lopez J, Santoro A, et al. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma
(KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. Lancet Oncol 2017;18:623-30. DOI
PubMed
15. Calabrò L, Morra A, Fonsatti E, et al. Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant
malignant mesothelioma: an open-label, single-arm, phase 2 study. Lancet Respir Med 2015;3:301-9. DOI PubMed
16. Maio M, Scherpereel A, Calabrò L, et al. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma
(DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. Lancet Oncol
2017;18:1261-73. DOI PubMed
17. Calabrò L, Morra A, Giannarelli D, et al. Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1):
an open-label, non-randomised, phase 2 study. Lancet Respir Med 2018;6:451-60. DOI PubMed
18. Scherpereel A, Mazieres J, Greillier L, et al. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural
mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. Lancet Oncol
2019;20:239-53. DOI PubMed
19. Popat S, Curioni-Fontecedro A, Dafni U, et al. A multicentre randomised phase III trial comparing pembrolizumab versus single-agent
chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15)
PROMISE-meso trial. Ann Oncol 2020;31:1734-45. DOI PubMed
20. Yap TA, Nakagawa K, Fujimoto N, et al. Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-
label, single-arm, phase 2 KEYNOTE-158 study. Lancet Respir Med 2021;9:613-21. DOI PubMed
21. Fennell DA, Kirkpatrick E, Cozens K, et al. CONFIRM: a double-blind, placebo-controlled phase III clinical trial investigating the
effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial. Trials 2018;19:233. DOI
PubMed PMC
22. Fennell D, Ottensmeier C, Califano R, et al. Nivolumab versus placebo in relapsed malignant mesothelioma: preliminary results from
the CONFIRM phase 3 trial. 2020 World Conference on Lung Cancer Singapore 2021. DOI
23. Fennell D, Ottensmeier C, Califano R, et al. PS01.11 nivolumab versus placebo in relapsed malignant mesothelioma: the CONFIRM
phase 3 trial. J Thorac Oncol 2021;16:S62. DOI
24. Zalcman G, Peters S, Mansfield AS, et al. Checkmate 743: A phase 3, randomized, open-label trial of nivolumab (nivo) plus
ipilimumab (ipi) vs pemetrexed plus cisplatin or carboplatin as first-line therapy in unresectable pleural mesothelioma. J Clin Oncol
2017;35:TPS8581. DOI
25. Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al; KEYNOTE-189 Investigators. Pembrolizumab plus chemotherapy in metastatic non-
small-cell lung cancer. N Engl J Med 2018;378:2078-92. DOI PubMed
26. Forde, P. M., et al. PrE0505: Phase II multicenter study of anti-PD-L1, durvalumab, in combination with cisplatin and pemetrexed for
the first-line treatment of unresectable malignant pleural mesothelioma (MPM)-A PrECOG LLC study. J Clin Oncol 2020;38:9003.
DOI
27. Nowak AK, Lesterhuis WJ, Kok P, et al. Durvalumab with first-line chemotherapy in previously untreated malignant pleural
mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in. Lancet Oncol 2020;21:1213-23. DOI PubMed
28. Scagliotti GV, Gaafar R, Nowak AK, et al. Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients
with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet
Respir Med 2019;7:569-80. DOI PubMed